08:34 AM EDT, 09/12/2025 (MT Newswires) -- Belite Bio ( BLTE ) said Friday that it has completed the last subject visit in the phase 3 clinical trial evaluating Tinlarebant for the treatment of Stargardt disease type 1.

The drug development company said it expects to report the top-line results from the trial in Q4 and plans to file a new drug application in H1 of 2026.

Tinlarebant is an oral therapy intended to reduce the accumulation of vitamin A-based toxins that cause retinal disease in Stargardt disease type 1, among others, the company said.